Pliant Therapeutics Inc Aktie News

One complete response and three partial responses observed  in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation of a Phase 1b expansion trial in 2026 Strong cash position supports planned operations through 2028 SOUTH SAN FRANCISC...

SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer...

Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate updat...

BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today p...

Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Compa...